Cinnamon (specifically Cinnamomum cassia) contains cinnamaldehyde and type A procyanidins that may modestly improve insulin sensitivity — but the clinical evidence is inconsistent, the effects are small, and the dose required for potential benefit raises safety concerns about coumarin content.
What the Evidence Shows
A 2013 meta-analysis in the Annals of Family Medicine pooling 10 RCTs found that cinnamon supplementation reduced fasting glucose by an average of 24.6 mg/dL — but the studies were highly heterogeneous in dose (1–6g daily), duration (40 days to 4 months), form (whole cinnamon vs extract), and population (healthy vs diabetic). A 2019 Cochrane review was less enthusiastic, concluding that the evidence was insufficient to recommend cinnamon for glycemic management due to study quality limitations.
The proposed mechanism: type A procyanidins in cinnamon mimic insulin's effect on insulin receptor signaling, enhancing glucose uptake in cell culture studies. Cinnamaldehyde may also support AMPK activation, though less potently than berberine.
The Coumarin Concern
Cassia cinnamon (the most common and cheapest type) contains significant coumarin — a compound that is hepatotoxic at high doses. The European Food Safety Authority set a tolerable daily intake of 0.1mg coumarin per kg of body weight. At the 3–6g cinnamon doses used in some studies, coumarin intake would exceed this limit. Ceylon cinnamon ("true cinnamon") contains negligible coumarin but is more expensive and has less clinical research.
The Verdict
Cinnamon is "modestly supported but not reliable" for blood sugar management. Adding it to food is fine and may provide small benefits. Using it as a primary glucose management strategy is not evidence-based. For serious metabolic support, berberine has far more robust and consistent clinical evidence. Berbercol provides berberine at a clinically studied dose alongside bergamot for comprehensive metabolic support.
Ceylon vs Cassia: A Deeper Look
The two main types of cinnamon differ significantly beyond coumarin content. Cassia cinnamon (Cinnamomum cassia, also called Chinese cinnamon) is what most people buy at grocery stores — it has a stronger, more pungent flavor and contains 1-2% coumarin by weight. Ceylon cinnamon (Cinnamomum verum, also called "true cinnamon") is lighter in color, more delicate in flavor, and contains only trace amounts of coumarin (0.004% — roughly 250 times less than cassia).
The irony is that most clinical trials showing glucose benefits used cassia — not Ceylon — making it impossible to determine whether Ceylon would produce similar metabolic effects at equivalent doses. The active compounds responsible for insulin-sensitizing effects (type A procyanidins, cinnamaldehyde) are present in both types, but the relative concentrations differ. Ceylon may work — but the honest answer is we don't have the clinical data to confirm it.
Context: Where Cinnamon Fits in the Evidence Hierarchy
When compared head-to-head with other blood sugar support nutrients, cinnamon's evidence is modest. Berberine has multiple large RCTs with HbA1c reductions of 0.5-1.0%. Chromium has meta-analyses showing consistent fasting glucose reductions. Inositol has robust PCOS-specific insulin resistance data. Cinnamon's evidence is smaller in scale, less consistent, and shows smaller effect sizes. It belongs in the "potentially helpful addition" category rather than the "clinically proven primary intervention" category.
Frequently Asked Questions
Which type of cinnamon is better for blood sugar?
Most studies used cassia cinnamon, which has more clinical evidence but also more coumarin. Ceylon cinnamon is safer for high doses but less studied. The honest answer: if you want reliable glucose support, berberine has better evidence than either type of cinnamon.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
